GSE182680 GSE182683 dexamethasone 7 v 6 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE182680_GSE182683_dexamethasone_7_v_6_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE182680_GSE182683_dexamethasone_7_v_6_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE182680_GSE182683_dexamethasone_7_v_6_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE182680_GSE182683_dexamethasone_7_v_6_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

WD repeat domain 46

Gene

differentiation antagonizing non-protein coding RNA

Gene

small nucleolar RNA host gene 3

Gene

small nucleolar RNA host gene 16

Gene

cytoskeleton regulator RNA

Gene

small nucleolar RNA host gene 15

Gene

VPS9D1 antisense RNA 1

Gene

ABCF2-H2BK1 readthrough

Gene

CDK6 antisense RNA 1

Gene

long intergenic non-protein coding RNA 339

  • Gene

    WD repeat domain 46


  • Gene

    differentiation antagonizing non-protein coding RNA


  • Gene

    small nucleolar RNA host gene 3


  • Gene

    small nucleolar RNA host gene 16


  • Gene

    cytoskeleton regulator RNA


  • Gene

    small nucleolar RNA host gene 15


  • Gene

    VPS9D1 antisense RNA 1


  • Gene

    ABCF2-H2BK1 readthrough


  • Gene

    CDK6 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 339

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.